Camlin Fine Sciences Ltd

- Camlin Fine Sciences is not currently planning any fresh loans as of the latest earnings call. - Some growth in turnover may require additional working capital, but it is not expected to increase overall debt by the end of next year. - The company plans to repay around Rs. 25 crores of long-term loans over the year. - No mention of any new equity fundraising was made in the call or transcript. - Repurposing projects in Europe and China, involving capex about $2-3 million each, are planned but expected to be funded from internal accruals or existing resources, no new fundraising indicated. Overall, Camlin Fine Sciences expects manageable debt levels with no significant fresh debt or equity raise planned in the near future.

- The Italy plant is being repurposed to produce MEHQ and Guaiacol, with financial closure pending; project stabilization and commercialization expected by end of FY25 (Page 13-14). - Planned capex for repurposing Europe plant is estimated at $2 million to $3 million (Page 6). - China plant repurposing investment is around Rs. 25 crores (~$3 million) (Page 6). - MEHQ and Guaiacol production in Italy projected to start contributing commercially in FY26 after validation and stabilization in FY25 (Page 13). - No new significant loans planned; some working capital may be needed for growth, but overall debt expected to remain stable with Rs. 25 crores of long-term loan repayment planned (Page 14-15). - No further major write-offs or unaccounted losses expected; legacy issues accounted for (Page 14-15).

- Blends business expected to grow from Rs. 780 crores (FY24) to over Rs. 1,000 crores in FY25. - Vanillin business projected to contribute around Rs. 200 crores in revenue in FY25. - Hydroquinone and downstream products expected to add Rs. 600-700 crores revenue. - Total conservative revenue outlook for FY25 is Rs. 1,800 - Rs. 1,900 crores, reflecting ~10% growth. - Volume growth seen in TBHQ and BHA by 10-15% despite price reductions. - North America and Brazil subsidiaries showing strong sales growth and positive EBITDA, likely to continue. - Vanillin plant capacity utilization anticipated at 40-50% in FY25, ramping up sale and market share, including targeting 400-500 tons in India. - Market demand expected to improve towards end of FY25 with possible price recovery. - Repurposing of European and China plants planned to support future growth with CAPEX around $3 million each.

- Company targets 10% to 15% revenue growth in FY25 across key businesses including blends, vanillin, and others. - Blends business expected to grow from ~Rs. 780 crores to over Rs. 1,000 crores with EBITDA margins in high teens (Rs. 180-190 crores EBITDA). - Vanillin business anticipated to achieve Rs. 200+ crores revenue and about Rs. 40-45 crores EBITDA by converting prior catechol losses to profit. - Consolidated EBITDA guidance for FY25 is Rs. 180-200 crores, translating to 10-12% EBITDA margin. - Losses from Europe and China operations expected around $3 million EBITDA level in FY25, reduced from FY24. - No further significant write-offs anticipated beyond legacy issues. - Price improvements expected towards end of FY25, supporting margin recovery. - New product lines (MEHQ, Guaiacol) in Italy to start contributing from end of FY25 and more fully in FY26.

- For vanillin, the company is targeting about 2,500 tons of orders, including both long-term contracts and spot orders. - Client approvals for vanillin are underway, with some long-term contracts expected to start soon. - The company has supplied large commercial lots of Negolyte to Lockheed Martin; discussions for a larger plant and increased capacity will begin around Q2 FY25. - Existing vanillin orders have good visibility over the next 2-3 months, combining both confirmed and potential spot business. - Growth in blends business and subsidiaries in the Americas indicates sustained positive momentum and order pipeline.